These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38106693)

  • 1. Assessing Adherence to Cardiac Monitoring Guidelines in Trastuzumab-Treated Breast Cancer Patients: Insights From a Tertiary Hospital.
    Alhuthali A; Alshammari A; Saleh K; Jaffal M; Bajnaid E; Almutairi MS; Almuylibi Z; Alghanmi A; Alnuhait M
    Cureus; 2023 Nov; 15(11):e48832. PubMed ID: 38106693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
    Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression.
    Yu L; Allen R; Jia L; Sun T; Isakoff SJ; Scherrer-Crosbie M; Kehlmann AM; Zheng H; Ly A; Walmsley CS; Hesler K; Varasteh AN; Pinto CJ; McLoughlin DE; Wu W; Wang X
    Front Oncol; 2022; 12():809715. PubMed ID: 35592673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review.
    Jafari L; Akhter N
    Breast Cancer Res Treat; 2021 Apr; 186(2):295-303. PubMed ID: 33481134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
    Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy.
    Alowais SA; Luk SO; Kim EB; Alsuhebany N; Zangardi M
    J Oncol Pharm Pract; 2023 Aug; ():10781552231193149. PubMed ID: 37528623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab.
    Bouwer NI; Liesting C; Kofflard MJM; Sprangers-van Campen SM; Brugts JJ; Kitzen JJEM; Fouraux MA; Levin MD; Boersma E
    Cardiooncology; 2019; 5():4. PubMed ID: 32154011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study.
    Moey MYY; Liles DK; Carabello BA
    Cardiooncology; 2019; 5():9. PubMed ID: 32154015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.
    Ayres LR; de Almeida Campos MS; de Oliveira Gozzo T; Martinez EZ; Ungari AQ; de Andrade JM; Pereira LR
    Int J Clin Pharm; 2015 Apr; 37(2):365-72. PubMed ID: 25637407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer.
    Sato A; Yoshihisa A; Miyata-Tatsumi M; Oikawa M; Kobayashi A; Ishida T; Ohtake T; Takeishi Y
    Mol Clin Oncol; 2019 Jan; 10(1):37-42. PubMed ID: 30655975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab.
    Andersson AE; Linderholm B; Giglio D
    Acta Oncol; 2021 Apr; 60(4):475-481. PubMed ID: 33191817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
    Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L
    Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
    Davis CC; Zelnak A; Eley JW; Goldstein DA; Switchenko JM; McKibbin T
    Ann Pharmacother; 2016 Sep; 50(9):712-7. PubMed ID: 27307412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.